Innovative Pharmaceutical Biotech (HKG:0399) said it plans to change its name to Starcoin Group Limited and increase its authorized share capital to HK$1.2 billion, according to a late-Wednesday Hong Kong bourse filing.
Shares of the company were down about 8% in morning trade on Thursday.
The proposed name change, which also includes adopting a new Chinese name, is intended to refresh the company's corporate image and support future business development, the company said.
Separately, it plans to raise its authorized share capital to HK$1.2 billion from HK$500 million by creating 70 billion new shares.
While there are currently no immediate plans to issue new shares, the increase is intended to provide flexibility for future expansion, the filing said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。